Reproductive Centre Gets Green Light to Resume Full Services After Sample Mix-Up
HK01 · 4 SOURCES1 day ago2 MIN
Summary
The Human Reproductive Technology Administration approved He Yu Reproductive Medical Centre to resume full services from October 6, 2026, after the centre addressed deficiencies identified following an embryo biopsy tissue sample mismatch incident. The centre had been operating under restrictions since July 8, when the administration suspended 14 of its 17 treatment services after discovering that eight out of nine embryo samples sent to a Chinese University of Hong Kong diagnostic centre were mismatched. Following a series of inspections and the implementation of comprehensive improvement measures, including upgraded laboratory security and staff training, regulators determined the centre could safely resume normal operations.
Key Points
- He Yu Reproductive Medical Centre can resume all 17 licensed treatment services starting October 6, 2026
- The centre had operated with only 3 services (gamete/embryo storage) since July 8 when 14 services were suspended
- A Malaysian female employee was suspected of mishandling samples and making false statements to cover up the error; she fled to Malaysia on July 24 after giving a police warning statement and is now wanted
- Eight of nine embryo biopsy tissue samples sent to the CUHK diagnostic centre belonged to different patients' parents
- Improvements implemented include enhanced sample processing procedures, CCTV installation, biometric authentication systems, and improved sample identification protocols
Why It Matters
This case highlights the critical importance of quality control and accountability in reproductive technology services, where errors can have lifelong consequences for families. The administration has also initiated a review of the Code of Practice for Reproductive Technology and Embryo Research, with a target to complete revisions by next year that will strengthen accident reporting mechanisms and biosample security standards across all licensed centres in Hong Kong .
This case highlights the critical importance of quality control and accountability in reproductive technology services, where errors can have lifelong consequences for families. The administration has also initiated a review of the Code of Practice for Reproductive Technology and Embryo Research, with a target to complete revisions by next year that will strengthen accident reporting mechanisms and biosample security standards across all licensed centres in Hong Kong .